Relationship between obesity, inflammation and insulin resistance: new concepts;Les relations entre obésité, inflammation et insulinorésistance : acquisitions récentes

Comptes Rendus - Biologies

Volumn 329, Issue 8, 2006, Pages 587-597

  Fève, Bruno ^a   Bastard, Jean Philippe ^a   Vidal, Hubert ^a  

^a INSERM   (France)

Author keywords

Adipocyte; Adipokines; Diabetes; Macrophage; Metabolic syndrome; Obesity; Visceral adipose tissue

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VISFATIN;

CYTOLOGY; DIABETES; METABOLISM; OBESITY; PATHOLOGY; PHYSIOLOGY;

ADIPOCYTE; CARDIOVASCULAR DISEASE; CELL INFILTRATION; ENDOCRINE FUNCTION; ENERGY CONSERVATION; GLUCOSE TOLERANCE; HORMONE RELEASE; HUMAN; HYPERLEPTINEMIA; IMMUNITY; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MACROPHAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RISK FACTOR; SHORT SURVEY; WHITE ADIPOSE TISSUE;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INSULIN RESISTANCE; OBESITY;

EID: 33746148265     PISSN: 16310691     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crvi.2006.03.020     Document Type: Short Survey

References (94)

1. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
2. Fried S.K., Bunkin D.A., and Grennberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83 (1998) 847-850
3. Bastard J.-P., Maachi M., Tran Van Nhieu J., Jardel C., Bruckert E., Grimaldi A., Robert J.-J., Capeau J., and Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab. 87 (2002) 2084-2089
4. Samad F., Yamamoto K., Pandey M., and Loskutoff D.J. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol. Med. 3 (1997) 37-48
5. Samad F., Yamamoto K., and Loskutoff D.J. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J. Clin. Invest. 97 (1996) 37-46
6. Sartipy P., and Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl Acad. Sci. USA 100 (2003) 7265-7270
7. van Dielen F.M., Buurman W.A., Hadfoune M., Nijhuis J., and Greve J.W. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J. Clin. Endocrinol. Metab. 89 (2004) 4062-4068
8. Cottam D.R., Mattar S.G., Barinas-Mitchell E., Eid G., Kuller L., Kelley D.E., and Schauer P.R. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes. Surg. 14 (2004) 589-600
9. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., and Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J. Am. Med. Assoc. 289 (2003) 1799-1804
10. Ryan A.S., and Nicklas B.J. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care 27 (2004) 1699-1705
11. Rosen B.S., Cook K.S., Yaglom J., Groves D.L., Volanakis J.E., Damm D., White T., and Spiegelman B.M. Adipsin and complement factor D activity: an immune-related defect in obesity. Science 244 (1989) 1483-1487
12. Cousin B., Munoz O., Andre M., Fontanilles A.M., Dani C., Cousin J.-L., Laharrrague P., Casteilla L., and Penicaud L. A role for preadipocytes as macrophage-like cells. FASEB J. 13 (1999) 305-312
13. Charrière G., Cousin B., Arnaud E., Andre M., Bacou F., Penicaud L., and Casteilla L. Preadipocyte conversion to macrophage. Evidence of plasticity. J. Biol. Chem. 278 (2003) 9850-9855
14. Totonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
15. Nagy L., Totonoz P., Alvarez J.G., Chen H., and Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93 (1998) 229-240
16. Makowski L., Boord J.B., Maeda K., Babaev V.R., Uysal K.T., Morgan M.A., Parker R.A., Suttles J., Fazio, Hotamisligil G.S., and Linton M.F. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7 (2001) 699-705
17. Das U.N. Is metabolic syndrome X an inflammatory condition?. Exp. Biol. Med. (Maywood) 227 (2002) 989-997
18. Ford E.S. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 168 (2003) 351-358
19. Das U.N. Obesity, metabolic syndrome X, and inflammation. Nutrition 18 (2002) 430-432
20. Albert M.A., Glynn R.J., and Ridker P.M. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 108 (2003) 161-165
21. Van Der Meer I.M., De Maat M.P., Hak A.E., Kiliaan A.J., Del Sol A.I., Van Der Kuip D.A., Nijhuis R.L., Hofman A., and Witteman J.C. C-Reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: The Rotterdam Study. Stroke 33 (2002) 2750-2755
22. Luc G., Bard J.-M., Juhan-Vague I., Ferrières J., Evans A., Amouyel P., Arveiler D., Fruchart J.-C., Ducimetière P., and PRIME Study Group. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: The PRIME Study. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1255-1261
23. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336 (1997) 973-979
24. Engstrom G., Hedblad B., Stavenow L., Lind P., Janzon L., and Lindgarde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 52 (2003) 2097-2101
25. Mosca L. C-reactive protein - to screen or not to screen?. N. Engl. J. Med. 347 (2002) 1615-1617
26. Castell J.V., Gomez-Lechon M.J., David M., Hirano T., Kishimoto T., and Heinrich P.C. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 232 (1988) 347-350
27. Barzilay J.I., Abraham L., Heckbert S.R., Cushman M., Kuller L.H., Resnick H.E., and Tracy R.P. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50 (2001) 2384-2389
28. Uysal K.T., Wiesbrock S.M., Marino M.W., and Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389 (1997) 610-614
29. Fernandes G., Handwerger B.S., Yunis E.J., and Brown D.M. Immune response in the mutant diabetic C57BL/Ks-dt+ mouse. Discrepancies between in vitro and in vivo immunological assays. J. Clin. Invest. 61 (1978) 243-250
30. Farooqi I.S., Materese G., Lord G.M., Keogh J.M., Lawrence E., Agwu C., Sanna V., Jebb S.A., Perna F., Fontana S., Lechler R.I., DePaoli A.M., and O'Rahilly S.A. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110 (2002) 1093-1103
31. Chandra R.K. Cell-mediated immunity in genetically obese C57BL/6J ob/ob) mice. Am. J. Clin. Nutr. 331 (1980) 13-16
32. Lord G.M., Materese G., Howard J.K., Baker R.J., Bloom S.R., and Lechler R.I. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394 (1998) 897-901
33. Soukas A., Cohen P., Socci N.D., and Friedman J.M. Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev. 14 (2000) 963-980
34. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003) 1796-1808
35. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., and Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112 (2003) 1821-1830
36. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., Wang S., Fortier M., Greenberg A.S., and Obin M.S. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid. Res. 46 (2005) 2347-2355
37. Clement K., Viguerie N., Poitou C., Carette C., Pelloux V., Curat C.A., Sicard A., Rome S., Benis A., Zucker J.D., Vidal H., Laville M., Barsh G.S., Basdevant A., Stich V., Cancello R., and Langin D. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J. 18 (2004) 1657-1669
38. Cancello R., Henegar C., Viguerie N., Taleb S., Poitou C., Rouault C., Coupaye M., Pelloux V., Hugol D., Bouillot J.L., Bouloumie A., Barbatelli G., Cinti S., Svensson P.A., Barsh G.S., Zucker J.D., Basdevant A., Langin D., and Clement K. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54 (2005) 2277-2286
39. Curat C.A., Miranville A., Sengenes C., Diehl M., Tonus C., Busse R., and Bouloumie A. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 53 (2004) 1285-1292
40. Tchoukaloya Y.D., Sarr M.G., and Jensen M.D. Measuring committed preadipocytes in human adipose tissue from severely obese patients by using adipocyte fatty acid binding protein. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287 (2004) R1132-R1140
41. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112 (2003) 1785-1788
42. Wellen K.E., and Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 115 (2005) 1111-1119
43. Cousin B., André M., Villena P., Casteilla L., and Penicaud L. Human adipose cells as candidates in defense and tissue remodeling phenomena. Biochem. Biophys. Res. Commun. 309 (2003) 502-505
44. Christiansen T., Richelsen B., and Bruun J.M. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int. J. Obes. 29 (2005) 146-150
45. Avogaro A., and de Kreutzenberg S.V. Mechanisms of endothelial dysfunction in obesity. Clin. Chim. Acta 360 (2005) 9-26
46. Trayhurn P., and Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 92 (2004) 347-355
47. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
48. Ahima R.S., and Flier J.S. Leptin. Annu. Rev. Physiol. 62 (2000) 413-437
49. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., Ohannesian J.P., Marco C.C., McKee L.J., Bauer T.L., and Caro J.F. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334 (1996) 292-295
50. Vidal H., Auboeuf D., De Vos P., Staels B., Riou J.-P., Auwerx J., and Laville M. The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. J. Clin. Invest. 98 (1996) 251-255
51. Lefebvre A.-M., Laville M., Vega N., Riou J.-P., van Gaal L., Auwerx J., and Vidal H. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47 (1998) 98-103
52. Loffreda S., Yang S.Q., Lin H.Z., Karp C.L., Brengman M.L., Wang D.J., Klein A.S., Bulkley G.B., Bao C., Noble P.W., Lane M.D., and Diehl A.M. Leptin regulates proinflammatory immune responses. FASEB J. 12 (1998) 57-65
53. van Dielen F.M., van't Veer C., Schols A.M., Soeters P.B., Buurman W.A., and Greve J.W. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int. J. Obes. Relat. Metab. Disord. 25 (2001) 1759-1766
54. Dusserre E., Moulin P., and Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim. Biophys. Acta 1500 (2000) 88-96
55. Montague C.T., Prins J.B., Sanders L., Zhang J., Sewter C.P., Digby J., Byrne C.D., and O'Rahilly S. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47 (1998) 1384-1391
56. Koistinen H.A., Bastard J.-P., Dusserre E., Ebeling P., Zegari N., Andreelli F., Jardel C., Donner M., Meyer L., Moulin P., Hainque B., Riou J.-P., Laville M., Koivisto V.A., and Vidal H. Subcutaneous adipose tissue expression of tumour necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects. Eur. J. Clin. Invest. 30 (2000) 302-310
57. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D.R., Miles J.M., Yudkin J.S., Klein S., and Coppack S.W. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82 (1997) 4196-4200
58. Fain J.N., Madan A.K., Hiler M.L., Cheema P., and Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145 (2004) 2273-2282
59. Maachi M., Piéroni L., Bruckert E., Jardel C., Fellahi S., Hainque B., Capeau J., and Bastard J.-P. Systemic low grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women. Int. J. Obes. 28 (2004) 993-997
60. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
61. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
62. Nonogaki K., Fuller G.M., Fuentes N.L., Moser A.H., Staprans I., Grunfeld C., and Feingold K.R. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136 (1995) 2143-2149
63. Bastard J.-P., Jardel C., Bruckert E., Blondy P., Capeau J., Laville M., Vidal H., and Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 85 (2000) 3338-3342
64. Ihle J.N., Witthuhn B.A., Quelle F.W., Yamamoto K., and Silvennoinen O. Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13 (1995) 369-398
65. Kroder G., Bossenmaier B., Kellerer M., Capp E., Stoyanov B., Mühlhöfer A., Berti L., Horikoshi H., Ullrich A., and Häring H. Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J. Clin. Invest. 97 (1996) 1471-1477
66. Mooney R.A., Senn J., Cameron S., Inamdar N., Boivin L.M., Shang Y., and Furlanetto R.W. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J. Biol. Chem. 276 (2001) 25889-25893
67. Lagathu C., Bastard J.-P., Auclair M., Maachi M., Capeau J., and Caron M. Chronic Interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: Prevention by Rosiglitazone. Biochem. Biophys. Res. Commun. 311 (2003) 372-379
68. Rieusset J., Bouzakri K., Chevillotte E., Ricard N., Jacquet D., Bastard J.-P., Laville M., and Vidal H. SOCS (Suppressor Of Cytokine Signaling)-3 Expression and Insulin Resistance in Skeletal Muscle of Obese and Type 2 Diabetic Patients. Diabetes 53 (2004) 2232-2241
69. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., and Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (1996) 665-668
70. Grimble R.F. Inflammatory status and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care 5 (2002) 551-559
71. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocrinol. Rev. 26 (2005) 439-451
72. Lihn A.S., Bruun J.M., He G., Pedersen S.B., Jensen P.F., and Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol. Cell. Endocrinol. 219 (2004) 9-15
73. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8 (2002) 1288-1295
74. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., Hotta K., Nishida M., Takahashi M., Nakamura T., Yamashita S., Funahashi T., and Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
75. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., Ishigami M., Kuriyama H., Kishida K., Nishizawa H., Hotta K., Muraguchi M., Ohmoto Y., Yamashita S., Funahashi T., and Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
76. Arita Y., Kihara S., Ouchi N., Maeda K., Kuriyama H., Okamoto Y., Kumada M., Hotta K., Nishida M., Takahashi M., Nakamura T., Shimomura I., Muraguchi M., Ohmoto Y., Funahashi T., and Matsuzawa Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105 (2002) 2893-2898
77. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., and Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signalling through a camp-dependent pathway. Circulation 102 (2000) 1296-1301
78. Bruun J.M., Lihn A.S., Verdich C., Pedersen S.B., Toubro S., Astrup A., and Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E527-E533
79. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N.H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., and Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
80. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.R., Ahima R.S., and Lazar M.A. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
81. Kim K.H., Lee K., Moon Y.S., and Sul H.K. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J. Biol. Chem. 276 (2001) 11252-11256
82. Jackson M.B., Osei S.Y., and Ahima R.S. The endocrine role of adipose tissue: focus on adiponectin and resistin. Curr. Opin. Endocrinol. Diabetes 12 (2005) 163-170
83. Ebstein W. Zur therapie des diabetes mellitus, insbesondere über die Answendung des salicylsauren natron bei demselben. Berlin Klin. Wochenschr. 13 (1876) 337-340
84. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., and Shoelson S.E. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293 (2001) 1673-1677
85. Kim J.K., Kim Y.J., Fillmore J.J., Chen Y., Moore I., Lee J., Yuan M., Li Z.W., Karin M., Perret P., Shoelson S.E., and Shulman G.I. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 108 (2001) 437-446
86. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., and Shoelson S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11 (2005) 183-190
87. Hirosumi J., Tuncman G., Chang L., Görgün C.Z., Uysal K.T., Maeda K., Karin M., and Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
88. Nakatani Y., Kaneto H., Kawamori D., Hatazaki M., Miyatsuka T., Matsuoka T.A., Kajimoto Y., Matsuhisa M., Yamasaki Y., and Hori M. Modulation of the JNK pathway in liver affects insulin resistance status. J. Biol. Chem. 279 (2004) 45803-45809
89. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
90. Gao Z., Zuberi A., Quon M.J., Dong Z., and Ze J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J. Biol. Chem. 278 (2003) 24944-24950
91. Shi X., Ding M., Dong Z., Chen F., Ye J., Wang S., Leonard S.S., Castranova V., and Vallyathan V. Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production. Mol. Cell. Biochem. 199 1-2 (1999) 93-102
92. Hundal R.S., Petersen K.F., Mayerson A.B., Randhawa P.S., Inzucchi S., Shoelson S.E., and Shulman G.I. Mechanism by which high-dose aspirin improves glucose metabolism in type-2 diabetes. J. Clin. Invest. 109 (2002) 1321-1326
93. Moller D.E., and Berger J.P. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int. J. Obes. Relat. Metab. Disord. (Suppl. 3) (2003) S17-S21
94. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23 (2002) 482-486